Table 1. Patient and treatment characteristics.
| Median age (years, range) | 56 (26–87) |
|---|---|
| Sex (n, %) | |
| Male | 71 (40.6) |
| Female | 104 (59.4) |
| ECOG | |
| 0 | 59 (33.7) |
| I | 84 (48.0) |
| II | 32 (18.3) |
| T stage | |
| T1 | 3 (1.7) |
| T2 | 36 (20.6) |
| T3 | 77 (44.0) |
| T4 | 59 (33.7) |
| N stage | |
| N0 | 66 (37.7) |
| N1 | 52 (29.7) |
| N2 | 46 (26.3) |
| N3 | 11 (6.3) |
| Staging | |
| BT | 22 (12.6) |
| MRI | 12 (6.9) |
| PET | 141 (80.5) |
| RT technique | |
| 3D-CRT | 30 (17.1) |
| IMRT | 145 (82.9) |
| RT dose | |
| Fraction dose | 2 Gy (1.8–2.3 Gy) |
| Fraction number | 30 (23–38) |
| Total dose | 60 Gy (45–72.6) |
| Concurrent chemotherapy (n, %) | |
| Cisplatin | 88 (50) |
| Carbo/taxol | 68 (39) |
| Others | 19 (11) |
Abbreviations: CRT: chemoradiotherapy, CT: computed tomography, IMRT: intensity modulated radiotherapy, MRI: magnetic resonance imaging, PET: positron emission tomography, RT: radiotherapy.